Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Overall Survival In Myelodysplastic Syndrome or Acute Myeloid Leukemia Patients Treated with On 01910.Na Correlates with Bone Marrow Blast Response

Lewis R Silverman, MD, Azra Raza, MD, Elaine M Sloand, MD, Peter L. Greenberg, MD, Francois E Wilhelm, MD, PhD

Blood (2010) 116 (21): 3998.

https://doi.org/10.1182/blood.V116.21.3998.3998

Published: 2010

Journal Articles

Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.

Daniel Shasha, MD, Fitzroy Dawkins, MD, Donghan Luo, PhD, Francois E. Wilhelm, MD, PhD, MSc, Marc Kamin, MD

Blood (2007) 110 (11): 3775.

https://doi.org/10.1182/blood.V110.11.3775.3775

Published: 2007

Journal Articles

Early vs Standard Intervention with an Extended Epoetin alfa (EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger Patients in a Randomized Clinical Trial.

Veena Charu, MD, Victor Moyo, MD, Donghan Luo, PhD, Francois E. Wilhelm, MD, PhD, MSc

Blood (2007) 110 (11): 3769.

https://doi.org/10.1182/blood.V110.11.3769.3769

Published: 2007

Journal Articles

Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U) Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in Chemotherapy-Induced Anemia (CIA).

Veena Charu, MD, Victor Moyo, MD, Donghan Luo, PhD, Francois E. Wilhelm, MD, PhD, MSc

Blood (2007) 110 (11): 3770.

https://doi.org/10.1182/blood.V110.11.3770.3770

Published: 2007

Journal Articles

Early and Standard Intervention with Epoetin Alfa (PROCRIT®) 120,000 Units (U) Every Three Weeks (Q3W) in Patients with Cancer Receiving Chemotherapy - Results of a Planned Interim Analysis.

John Glaspy, MD, Victor Moyo, MD, Marc Kamin, MD, Francois E. Wilhelm, MD,PhD,MSc

Blood (2006) 108 (11): 3774.

https://doi.org/10.1182/blood.V108.11.3774.3774

Published: 2006

Journal Articles

Epoetin alfa 80,000 U Every Three Weeks (Q3W) in Anemic Cancer Patients (pts) Not Receiving Chemotherapy (CT) or Radiation Therapy (RT).

Daniel Shasha, MD, Fitzroy Dawkins, MD, Francois E. Wilhelm, MD,PhD,MSc

Blood (2006) 108 (11): 3755.

https://doi.org/10.1182/blood.V108.11.3755.3755

Published: 2006

NARROW

Overall Survival In Myelodysplastic Syndrome or Acute Myeloid Leukemia Patients Treated with On 01910.Na Correlates with Bone Marrow Blast Response

Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.

Early vs Standard Intervention with an Extended Epoetin alfa (EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger Patients in a Randomized Clinical Trial.

Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U) Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in Chemotherapy-Induced Anemia (CIA).

Early and Standard Intervention with Epoetin Alfa (PROCRIT®) 120,000 Units (U) Every Three Weeks (Q3W) in Patients with Cancer Receiving Chemotherapy - Results of a Planned Interim Analysis.

Epoetin alfa 80,000 U Every Three Weeks (Q3W) in Anemic Cancer Patients (pts) Not Receiving Chemotherapy (CT) or Radiation Therapy (RT).

Email alerts

ASH Publications

American Society of Hematology

Overall Survival In Myelodysplastic Syndrome or Acute Myeloid Leukemia Patients Treated with On 01910.Na Correlates with Bone Marrow Blast Response

Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.

Early vs Standard Intervention with an Extended Epoetin alfa (EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger Patients in a Randomized Clinical Trial.

Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U) Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in Chemotherapy-Induced Anemia (CIA).

Early and Standard Intervention with Epoetin Alfa (PROCRIT®) 120,000 Units (U) Every Three Weeks (Q3W) in Patients with Cancer Receiving Chemotherapy - Results of a Planned Interim Analysis.

Epoetin alfa 80,000 U Every Three Weeks (Q3W) in Anemic Cancer Patients (pts) Not Receiving Chemotherapy (CT) or Radiation Therapy (RT).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only